RecruitingNAINTERVENTIONAL

Blood Clearance Kinetics of the Nucleosome and CTCF in Peritoneal Metastasis Colorectal Cancer.

This study is about making sure all cancer cells are gone after surgery for bowel cancer that has spread to the tummy lining (peritoneal metastasis). Currently, surgeons use their judgment to score how complete the surgery was. We are exploring new blood tests, called 'biomarkers,' that can detect tiny bits of cancer DNA or other cancer-related markers released into the blood. The aim is to find an objective way to see if any cancer cells are left behind after surgery. By understanding how these markers change in the blood, we hope to improve how doctors check for remaining disease and predict how well patients will do after treatment.

At a glance

Status

Recruiting

Phase

Sponsor

Hospices Civils de Lyon

Enrolment target

Start

06 May 2025

Estimated completion

20 Jun 2026

Peritoneal Carcinomatosis Peritoneal Metastases From Colorectal Cancer

What is this study about?

This study is looking into better ways to check if all cancer cells have been removed after surgery for a type of bowel cancer that has spread to the lining of the tummy, called the peritoneum. When bowel cancer spreads, it can go to places like the liver, lungs, or the peritoneum. If it spreads to the peritoneum, doctors sometimes recommend a special surgery to remove as much cancer as possible.

After this surgery, the surgeon gives a score based on how completely they think they've removed the cancer. This score is important, but it's based on what the surgeon sees. We want to find a more objective way to check if any tiny cancer cells, too small to see, are still present. This study is investigating new blood tests that can spot specific markers released by cancer cells into your bloodstream. By understanding how these markers behave, especially after surgery, we hope to create a biological 'score' that can tell us if any cancer is still lurking.

We also want to understand how general inflammation in the body might affect these new blood tests, as inflammation can sometimes confuse the results. To make sure these new tests are reliable, we’ll be comparing how they behave in different groups of people, including those having this specific cancer surgery, people with other types of bowel cancer, and those having different surgeries or conditions not related to cancer.

Key takeaways

Exploring new blood tests to detect tiny remaining cancer cells after surgery.
Aims to create a more objective way to check for cancer completeness.
Investigates bowel cancer spread to the tummy lining.
Compares new markers in different patient groups.
Could help improve future patient care and outcomes.

Who may be eligible?

To join this study, you need to be an adult over 18 years old and weigh at least 55 kg. You also need to agree to take part by signing a consent form.

There are different groups of people we are looking for. One main group is those with bowel cancer that has spread to the lining of the tummy, and who are planning to have surgery for it. We are particularly interested in those whose cancer does not produce a lot of a specific type of mucus. Other groups include people with bowel cancer (but without spread to the tummy lining), people with long-term inflammatory conditions not related to cancer, and those having surgery for other non-cancerous tummy problems like appendicitis or a burst bowel.

However, you cannot join if you have another active cancer (apart from the bowel cancer we're studying) or if you have an active, ongoing autoimmune disease.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you over 18 years old?
Do you weigh at least 55 kg?
Do you have bowel cancer that has spread to your tummy lining and are you having surgery for it?
Do you have an active autoimmune disease? (If yes, you likely can't join)
Do you have another active cancer (not bowel cancer)? (If yes, you likely can't join)

Answer every question to see your result.

What does participation involve?

If you join this study, you will have blood samples taken at different times. These blood samples will be used to look for the new cancer markers and to see how they change over time, especially around the time of your surgery. We will also monitor your general health. The total duration of your participation will depend on which group you are in, but the main focus is around the time of your surgery and the weeks following, to see how the markers clear from your blood.

Potential risks and benefits

By taking part, you could be contributing to important research that might improve how doctors check for remaining cancer and predict treatment success for future patients with bowel cancer. There are no direct benefits to your own treatment, as this is a research study to develop new tests. The main risk involves discomfort or bruising from blood draws. You are free to withdraw from the study at any time without giving a reason, and this will not affect your medical care.

Locations (1)

Hôpital Lyon Sud
Verified postcode
Pierre-Bénite, France· Recruiting

Common questions

What is peritoneal metastasis?

It's when bowel cancer cells spread to the lining of your tummy (abdomen), which is called the peritoneum.

What are 'biomarkers'?

Biomarkers are substances in your body, like certain molecules in your blood, that can indicate a disease or how your body is responding to treatment. In this study, we're looking for specific markers released by cancer cells.

Will taking part change my treatment?

No, this study is about developing new diagnostic tests, not changing your current medical treatment. Your medical care will continue as planned by your doctors.

Is this study safe for me?

The procedures in this study mostly involve blood tests, which are generally very safe. Your health will be monitored, and you can withdraw at any time.

What does 'cytoreduction surgery' mean?

It's a surgery specifically aimed at removing as much of the cancer as possible, especially when it has spread widely.

How to find out more

Vahan KEPENEKIAN, MD, PhD

vahan.kepenekian@chu-lyon.fr +33 478 862 371 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.